EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A fragment-based drug discovery developed on ciclopirox for inhibition of Hepatitis B virus core protein: An in silico study

Alireza Mohebbi iD, Touba Ghorbanzadeh, Shabnam Naderifar, Fattaneh Khalaj, Fatemeh Sana Askari, Ali Salehnia Sammak

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0285941 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Alireza Mohebbi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Virus Assembly, Hepatitis B. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Hepatitis B virus (HBV) core protein is an attractive target for preventing capsid assembly and viral replication. Drug repurposing strategies have introduced several drugs targeting HBV core protein. This study used a fragment-based drug discovery (FBDD) approach to reconstruct a repurposed core protein inhibitor to some novel antiviral derivatives. Auto Core Fragment in silico Screening (ACFIS) server was used for deconstruction-reconstruction of Ciclopirox in complex with HBV core protein. The Ciclopirox derivatives were ranked based on their free energy of binding (ΔGB). A quantitative structure affinity relationship (QSAR) was established on the Ciclopirox derivatives. The model was validated by a Ciclopirox-property-matched decoy set. A principal component analysis (PCA) was also assessed to define the relationship of the predictive variable of the QSAR model. 24-derivatives with a ΔGB (-16.56±1.46 Kcal.mol -1 ) more than Ciclopirox was highlighted. A QSAR model with a predictive power of 88.99% (F-statistics = 9025.78, corrected df(25), Pr > F = 0.0001) was developed by four predictive descriptors (ATS1p, nCs, Hy, F08[C-C]). The model validation showed no predictive power for the decoy set (Q 2 = 0). No significant correlation was observed between predictors. By directly attaching to the core protein carboxyl-terminal domain, Ciclopirox derivatives may be able to suppress HBV virus assembly and subsequent viral replication inhibition. Hydrophobic residue Phe23 is a critical amino acid in the ligand binding domain. These ligands share the same physicochemical properties that lead to the development of a robust QSAR mode. The same strategy may also be used for future drug discovery of viral inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Virus AssemblyHepatitis BHumansHepatitis B virusCiclopiroxVirus ReplicationAntiviral AgentsCapsid ProteinsDrug DiscoveryViral Core Proteins

Substanzen

CiclopiroxAntiviral AgentsCapsid ProteinsViral Core Proteins

Autor:innen und Institutionen

  • Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Vista Aria Rena Gene Inc., Golestan Province, Gorgan, Iran.
  • Department of Microbiology, Tehran North Branch, Islamic Azad University of Tehran, Tehran, Iran.
  • Department of Biotechnology, Brandenburg Technology University, Senftenberg, Germany.
  • Liver and Pancreatobiliary Diseases Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Digestive Diseases Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Alireza Mohebbi

Zitieren

APA

Mohebbi, A., Ghorbanzadeh, T., Naderifar, S., Khalaj, F., Askari, F. S., & Sammak, A. S. (2023). A fragment-based drug discovery developed on ciclopirox for inhibition of Hepatitis B virus core protein: An in silico study. PLOS ONE. https://doi.org/10.1371/journal.pone.0285941

Vancouver

Mohebbi A, Ghorbanzadeh T, Naderifar S, Khalaj F, Askari FS, Sammak AS. A fragment-based drug discovery developed on ciclopirox for inhibition of Hepatitis B virus core protein: An in silico study. PLOS ONE. 2023. doi:10.1371/journal.pone.0285941

BibTeX
@article{Mohebbi2023,
  author = {Mohebbi, Alireza and Ghorbanzadeh, Touba and Naderifar, Shabnam and Khalaj, Fattaneh and Askari, Fatemeh Sana and Sammak, Ali Salehnia},
  title = {A fragment-based drug discovery developed on ciclopirox for inhibition of Hepatitis B virus core protein: An in silico study},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0285941}
}
Kostenlos starten →